Trial Outcomes & Findings for Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults (NCT NCT05786521)

NCT ID: NCT05786521

Last Updated: 2025-05-04

Results Overview

Determine if there is any change in lean body mass

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

20 participants

Primary outcome timeframe

Baseline to 20 weeks

Results posted on

2025-05-04

Participant Flow

Participant milestones

Participant milestones
Measure
Semaglutide and Lifestyle Intervention
Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program. They will also be given semaglutide for 20 weeks. Semaglutide Injectable Product: Semaglutide will be started at 0.25mg once a week for 4 weeks followed by 0.5mg once weekly for 4 weeks followed by 1.0mg once a week for 12 weeks. Lifestyle Counseling: Lifestyle Counseling will be provided throughout study intervention
Lifestyle Intervention
Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program Lifestyle Counseling: Lifestyle Counseling will be provided throughout study intervention
Overall Study
STARTED
10
10
Overall Study
COMPLETED
10
10
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Semaglutide and Lifestyle Intervention
n=10 Participants
Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program. They will also be given semaglutide for 20 weeks. Semaglutide Injectable Product: Semaglutide will be started at 0.25mg once a week for 4 weeks followed by 0.5mg once weekly for 4 weeks followed by 1.0mg once a week for 12 weeks. Lifestyle Counseling: Lifestyle Counseling will be provided throughout study intervention
Lifestyle Intervention
n=10 Participants
Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program Lifestyle Counseling: Lifestyle Counseling will be provided throughout study intervention
Total
n=20 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Age, Categorical
>=65 years
10 Participants
n=99 Participants
10 Participants
n=107 Participants
20 Participants
n=206 Participants
Age, Continuous
71.9 years
STANDARD_DEVIATION 4.85 • n=99 Participants
73.4 years
STANDARD_DEVIATION 4.98 • n=107 Participants
72.65 years
STANDARD_DEVIATION 4.85 • n=206 Participants
Sex: Female, Male
Female
5 Participants
n=99 Participants
5 Participants
n=107 Participants
10 Participants
n=206 Participants
Sex: Female, Male
Male
5 Participants
n=99 Participants
5 Participants
n=107 Participants
10 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
5 Participants
n=99 Participants
4 Participants
n=107 Participants
9 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
5 Participants
n=99 Participants
6 Participants
n=107 Participants
11 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Region of Enrollment
United States
10 participants
n=99 Participants
10 participants
n=107 Participants
20 participants
n=206 Participants

PRIMARY outcome

Timeframe: Baseline to 20 weeks

Determine if there is any change in lean body mass

Outcome measures

Outcome measures
Measure
Semaglutide and Lifestyle Intervention
n=10 Participants
Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program. They will also be given semaglutide for 20 weeks. Semaglutide Injectable Product: Semaglutide will be started at 0.25mg once a week for 4 weeks followed by 0.5mg once weekly for 4 weeks followed by 1.0mg once a week for 12 weeks. Lifestyle Counseling: Lifestyle Counseling will be provided throughout study intervention
Lifestyle Intervention
n=10 Participants
Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program Lifestyle Counseling: Lifestyle Counseling will be provided throughout study intervention
Lean Body Mass Change
-1730.6 g
Interval -3063.0 to -398.0
-421 g
Interval -1745.0 to 911.0

Adverse Events

Semaglutide and Lifestyle Intervention

Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths

Lifestyle Intervention

Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Semaglutide and Lifestyle Intervention
n=10 participants at risk
Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program. They will also be given semaglutide for 20 weeks. Semaglutide Injectable Product: Semaglutide will be started at 0.25mg once a week for 4 weeks followed by 0.5mg once weekly for 4 weeks followed by 1.0mg once a week for 12 weeks. Lifestyle Counseling: Lifestyle Counseling will be provided throughout study intervention
Lifestyle Intervention
n=10 participants at risk
Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program Lifestyle Counseling: Lifestyle Counseling will be provided throughout study intervention
Gastrointestinal disorders
Abdominal pain
60.0%
6/10 • Number of events 7 • 20 weeks
10.0%
1/10 • Number of events 1 • 20 weeks

Additional Information

TIffany M Cortes, MD

University of Texas Health Science Center San Antonio

Phone: 210-450-3333

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place